| Literature DB >> 32005144 |
Huanhuan Su1,2, Dongmei Ma1, Huaping Zhu3, Zhigang Liu1, Fengying Gao1.
Abstract
BACKGROUND: Osmotic stress is a widespread phenomenon in aquatic animal. The ability to cope with salinity stress and alkaline stress is quite important for the survival of aquatic species under natural conditions. Tilapia is an important commercial euryhaline fish species. What's more tilapia is a good experimental material for osmotic stress regulation research, but the molecular regulation mechanism underlying different osmotic pressure of tilapia is still unexplored.Entities:
Keywords: Osmoregulation; Osmotic stress; Tilapia; Transcriptome
Mesh:
Substances:
Year: 2020 PMID: 32005144 PMCID: PMC6995152 DOI: 10.1186/s12864-020-6512-5
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Number of high-throughput raw reads, clean reads and mapped clean reads generated from tilapia gills mRNA library
| Sample | Number of raw reads | Q30 (%) | Number of clean reads | Q30 (%) | Mapped clean reads | Mapped ratio(%) |
|---|---|---|---|---|---|---|
| C1 | 75,721,168 | 88.544 | 74,808,692 | 89.44 | 52,233,344 | 69.8226 |
| C5 | 43,511,812 | 90.96 | 43,136,688 | 91.69 | 30,654,690 | 71.0641 |
| C6 | 44,022,606 | 91.22 | 43,713,040 | 91.85 | 32,352,233 | 74.0105 |
| S4 | 55,033,428 | 86.48 | 54,047,972 | 87.70 | 37,247,738 | 68.9161 |
| S5 | 64,567,494 | 86.92 | 63,504,896 | 88.06 | 43,706,215 | 68.8234 |
| S6 | 64,847,564 | 89.3 | 64,143,714 | 90.12 | 44,873,133 | 69.9572 |
| A4 | 54,989,278 | 85.66 | 53,892,592 | 86.98 | 36,759,709 | 68.2092 |
| A5 | 45,237,800 | 86.22 | 44,285,538 | 87.58 | 30,725,853 | 69.3812 |
| A6 | 44,832,372 | 90.99 | 44,459,288 | 91.71 | 32,794,998 | 73.7641 |
| SA4 | 44,979,952 | 90.99 | 44,613,938 | 91.7 | 33,268,715 | 74.5702 |
| SA5 | 46,376,590 | 91.01 | 46,009,836 | 91.71 | 33,172,654 | 72.099 |
| SA6 | 43,246,430 | 91.09 | 42,893,882 | 91.78 | 32,244,543 | 75.1728 |
Fig. 1Hierarchical cluster analysis of differentially expressed genes based on the data of log ratio fold change. Heat map showing differentially expressed mRNAs upon osmotic stress in hybrid tilapia. The expression heat map was generated with the value of log10FPKM. The color scale shows the levels of differentially expressed genes: red color indicates enhanced expression of mRNA and blue color indicates decrease in expression levels of mRNA
Fig. 2The number of differentially expressed DEGs in different groups
Fig. 3DEGs number and venn diagram of overlap of the different groups. a: DEGs number and venn diagram of overlap of the C vs. S, C vs. A and C vs. SA groups. b: DEGs number and venn diagram of overlap of the C vs. S, C vs. A, C vs. SA, S vs. SA and A vs. SA groups
Fig. 4Gene Ontology (GO) classification of assembled unigenes. a: C vs. S; b: C vs. A; c: C vs. SA; d: S vs. SA; e: A vs. SA
Osmoregulation-related differentially expressed genes (DEGs) regulated after stressed in group C vs. S, C vs. A and C vs. SA
| Groups | Gene name | Pathway ID | Log2 (Fold Change) | |
|---|---|---|---|---|
| chloride channel 2(clcn2) | K05011 | −2.57413 | 0.00005 | |
| two pore calcium channel protein 3(tpcn3) | K16897 | 1.32543 | 0.00005 | |
| transient receptor potential cation channel subfamily V member 4(TRPV4) | K04973 | −1.41868 | 0.00005 | |
| aquaporin-1(AQP1) | K09864 | 1.3813 | 0.00005 | |
| aquaporin-3(AQP3) | K09876 | −3.17706 | 0.00005 | |
| prolactin receptor (prlr) | K05081 | −1.16648 | 0.00005 | |
| potassium inwardly-rectifying channel subfamily J member 2(KCNJ2) | K04996 | 2.21687 | 0.00005 | |
| calcium/calmodulin-dependent protein kinase (CaM kinase) II (CAMK2) | K04515 | 1.80579 | 0.00005 | |
| hyperpolarization activated cyclic nucleotide-gated potassium channel 4(HCN4) | K04957 | −1.28146 | 0.00005 | |
| C-VS-S | phospholipid-translocating ATPase (ATP10b) | K01530 | −1.29862 | 0.00005 |
| carbonic anhydrase (CA) | K01672 | −1.53219 | 0.00005 | |
| carbonic anhydrase 4(CA4) | K18246 | 3.0621 | 0.00105 | |
| sodium/potassium/chloride transporter (SLC12A2/ NKCC1) | K10951 | 2.49218 | 0.00005 | |
| solute carrier family 9 (sodium/hydrogen exchanger), member 3(SLC9A3) | K12040 | −1.05992 | 0.00205 | |
| Na(+)/H(+) exchange regulatory cofactor NHE-RF2(SLC9A3R2/NHERF2) | K13358 | 1.04245 | 0.00005 | |
| sodium bicarbonate cotransporter (SLC4A4/NBC1) | K13575 | −1.50471 | 0.00005 | |
| mitogen-activated protein kinase 8(mapk4) | K06855 | 1.66571 | 0.00005 | |
| mitogen-activated protein kinase 8 interacting protein 3 | K04436 | 1.67422 | 0.0065 | |
| regulator of G-protein signaling (RGS) | K16449 | −3.14363 | 0.00005 | |
| Solute carrier family 9 (sodium/hydrogen exchanger), member 5(NHE5) | K14723 | 4.08758 | 0.00005 | |
| Chloride channel 2(CLCN2) | K05011 | 1.36324 | 0.00005 | |
| Aquaporin-3(AQP3) | K09876 | −1.57718 | 0.00005 | |
| Aquaporin-1(AQP1) | K09864 | 1.27087 | 0.00005 | |
| Carbonic anhydrase 4(CA4) | K18246 | 2.33457 | 0.00005 | |
| Transient receptor potential cation channel subfamily V member 6(trpv6) | K04975 | 2.87291 | 0.00005 | |
| Chloride channel 3/4/5(CLCN5) | K05012 | −1.23945 | 0.00005 | |
| Two pore calcium channel protein 3(TPCN3) | 0.00005 | 1.12829 | 0.00005 | |
| Potassium inwardly-rectifying channel subfamily J member 2(KCNJ2) | K04996 | 1.73207 | 0.00005 | |
| Hyperpolarization activated cyclic nucleotide-gated potassium channel 4(HCN4) | K04957 | −1.18463 | 0.00005 | |
| Potassium channel subfamily K member 5(KCNK5) | K04916 | 1.31934 | 0.00005 | |
| C-VS-A | Calcium/calmodulin-dependent protein kinase (cam kinase) II (CAMK2) | K04515 | −1.1669 | 0.004 |
| Phospholipid-translocating atpase (ATP10b) | K01530 | −1.11012 | 0.00005 | |
| Phospholipid-translocating atpase (ATP8b4) | K01530 | 1.25176 | 0.00005 | |
| Sodium/potassium-transporting atpase subunit alpha (ATP1A) | K01539 | −1.98927 | 0.00005 | |
| Solute carrier family 8 (sodium/calcium exchanger)(SLC8A1) | K05849 | 3.17412 | 0.00005 | |
| Solute carrier family 4 (anion exchanger), member 2(SLC4A2) | K13855 | −2.43824 | 0.00005 | |
| Sodium bicarbonate cotransporter (SLC4A4/NBC1) | K13575 | 1.30546 | 0.00005 | |
| Sodium/potassium/chloride transporterslc12a2/NKCC1) | K10951 | 1.05921 | 0.00005 | |
| MFS transporter, SP family, solute carrier family 2 member 8(SLC2A8) | K08145 | 1.82715 | 0.01315 | |
| Mitogen-activated protein kinase6(MAPK6) | K06855 | 1.12481 | 0.00005 | |
| Mitogen-activated protein kinase4 kinase 4(MAPK4k4) | K04407 | −1.96545 | 0.00005 | |
| Mitogen-activated protein kinase 8 interacting protein 3 | K04436 | 1.0482 | 0.00025 | |
| Regulator of G-protein signaling (rgs12) | K16449 | 1.23556 | 0.01035 | |
| Carbonic anhydrase (CA) | K01672 | −1.63577 | 0.00005 | |
| Carbonic anhydrase 4(CA4) | K18246 | 2.00696 | 0.00005 | |
| Potassium channel subfamily K member 5(kcnk5) | K04916 | 1.86814 | 0.00005 | |
| Transient receptor potential cation channel subfamily V member 6(TRPV6) | K04975 | 4.23057 | 0.00005 | |
| Calcium/calmodulin-dependent protein kinase (cam kinase) II (CAMK2) | K04515 | 1.29023 | 0.00005 | |
| Chloride channel 3/4/5(CLCN5) | K05012 | 1.20394 | 0.00005 | |
| Hyperpolarization activated cyclic nucleotide-gated potassium channel 4(HCN4) | K04957 | −1.36233 | 0.00005 | |
| C-VS-SA | Phospholipid-translocating atpase (ATP10b) | K01530 | −2.14108 | 0.0008 |
| Aquaporin-9(AQP9) | K09877 | 2.47715 | 0.0046 | |
| Aquaporin-3(AQP3) | K09876 | −2.15244 | 0.00005 | |
| Adenylate cyclase 3(ADCY3) | K08043 | 1.52349 | 0.0108 | |
| Sodium/potassium/chloride transporter (SLC12A2/NKCC1) | K10951 | 1.21719 | 0.00005 | |
| Sodium bicarbonate cotransporter (SLC4A4/NBC1) | K13575 | 1.23287 | 0.00005 | |
| Solute carrier family 8 (sodium/calcium exchanger)(SLC8A1) | K05849 | 4.74133 | 0.00005 | |
| Mitogen-activated protein kinase4(MAPK4) | K06855 | 1.36517 | 0.00005 | |
| Mitogen-activated protein kinase4 kinase 4(MAPKk4) | K04407 | 1.43318 | 0.0017 | |
| Regulator of G-protein signaling (RGS) | K16449 | −1.93502 | 0.00005 |
Comparative analysis of the KEGG pathways enriched in the three groups
| Group | Total | Payhway ID | Pathway description |
|---|---|---|---|
| S & A & SA | 25 | ko00100 | Steroid biosynthesis |
| ko05332 | Graft-versus-host disease | ||
| ko04657 | IL-17 signaling pathway | ||
| ko00512 | Mucin type O-glycan biosynthesis | ||
| ko05133 | Pertussis | ||
| ko05330 | Allograft rejection | ||
| ko05320 | Autoimmune thyroid disease | ||
| ko00660 | C5-Branched dibasic acid metabolism | ||
| ko00520 | Amino sugar and nucleotide sugar metabolism | ||
| ko05322 | Systemic lupus erythematosus | ||
| ko00260 | Glycine, serine and threonine metabolism | ||
| ko03430 | Mismatch repair | ||
| ko04111 | Cell cycle - yeast | ||
| ko01200 | Carbon metabolism | ||
| ko01230 | Biosynthesis of amino acids | ||
| ko00909 | Sesquiterpenoid and triterpenoid biosynthesis | ||
| ko00680 | Methane metabolism | ||
| ko04110 | Cell cycle | ||
| ko03030 | DNA replication | ||
| ko04940 | Type I diabetes mellitus | ||
| ko04612 | Antigen processing and presentation | ||
| ko00052 | Galactose metabolism | ||
| ko04964 | Proximal tubule bicarbonate reclamation | ||
| ko00643 | Styrene degradation | ||
| ko00240 | Pyrimidine metabolism | ||
| A & S | 2 | ko03050 | Proteasome |
| ko04115 | p53 signaling pathway | ||
| S & SA | 3 | ko00051 | Fructose and mannose metabolism |
| ko00010 | Glycolysis / Gluconeogenesis | ||
| ko00250 | Alanine, aspartate and glutamate metabolism | ||
| A & SA | 18 | ko04650 | Natural killer cell mediated cytotoxicity |
| ko00072 | Synthesis and degradation of ketone bodies | ||
| ko05166 | HTLV-I infection | ||
| ko04113 | Meiosis - yeast | ||
| ko00230 | Purine metabolism | ||
| ko00531 | Glycosaminoglycan degradation | ||
| ko02026 | Biofilm formation - | ||
| ko04145 | Phagosome | ||
| ko05203 | Viral carcinogenesis | ||
| ko05169 | Epstein-Barr virus infection | ||
| ko03420 | Nucleotide excision repair | ||
| ko01524 | Platinum drug resistance | ||
| ko00480 | Glutathione metabolism | ||
| ko05416 | Viral myocarditis | ||
| ko05168 | Herpes simplex infection | ||
| ko03460 | Fanconi anemia pathway | ||
| ko03440 | Homologous recombination | ||
| ko05130 | Pathogenic Escherichia coli infection | ||
| S | 9 | ko05310 | Asthma |
| ko00710 | Carbon fixation in photosynthetic organisms | ||
| ko04060 | Cytokine-cytokine receptor interaction | ||
| ko04512 | ECM-receptor interaction | ||
| ko00720 | Carbon 2fixation pathways in prokaryotes | ||
| ko00410 | beta-Alanine metabolism | ||
| ko04141 | Protein processing in endoplasmic reticulum | ||
| ko00910 | Nitrogen metabolism | ||
| ko00590 | Arachidonic acid metabolism | ||
| A | 6 | ko00511 | Other glycan degradation |
| ko00513 | Various types of N-glycan biosynthesis | ||
| ko04668 | TNF signaling pathway | ||
| ko05164 | Influenza A | ||
| ko00980 | Metabolism of xenobiotics by cytochrome P450 | ||
| ko00650 | Butanoate metabolism | ||
| SA | 12 | ko04978 | Mineral absorption |
| ko00640metabolism | Propanoate | ||
| ko02020 | Two-component system | ||
| ko00630 | Glyoxylate and dicarboxylate metabolism | ||
| ko05144 | Malaria | ||
| ko04514 | Cell adhesion molecules (CAMs) | ||
| ko00363 | Bisphenol degradation | ||
| ko05410 | Hypertrophic cardiomyopathy (HCM) | ||
| ko00521 | Streptomycin biosynthesis | ||
| ko00290 | Valine, leucine and isoleucine biosynthesis | ||
| ko00500 | Starch and sucrose metabolism | ||
| ko00770 | Pantothenate and CoA biosynthesis |
Fig. 5Gene Ontology (GO) classification of differential expression genes in group S, A, SA, S & A, S & SA, A & SA S, and A & SA. a: S; b: A; c: SA; d: S & A; e: S & SA; f: A & SA; g: S, A & SA
KEGG pathway analysis of DEGs expressed only in group S, not in other groups
| Pathway ID | Pathway | DEGs with pathway annotation (642) | |
|---|---|---|---|
| ko04060 | Cytokine-cytokine receptor interaction | 41(6.39%) | 1.13E-04 |
| ko04512 | ECM-receptor interaction | 22(3.43%) | 5.02E-04 |
| ko00010 | Glycolysis / Gluconeogenesis | 12(1.87%) | 1.29E-03 |
| ko04978 | Mineral absorption | 11(1.71%) | 1.65E-03 |
| ko00565 | Ether lipid metabolism | 10(1.56%) | 6.13E-04 |
| ko00591 | Linoleic acid metabolism | 7(1.09%) | 1.76E-03 |
| ko00710 | Carbon fixation in photosynthetic organisms | 7(1.09%) | 4.79E-05 |
| ko00410 | beta-Alanine metabolism | 7(1.09%) | 7.75E-04 |
| ko00592 | alpha-Linolenic acid metabolism | 6(0.93%) | 5.04E-04 |
| ko02024 | Quorum sensing | 5(0.78%) | 4.65E-04 |
| ko00524 | Neomycin, kanamycin and gentamicin biosynthesis | 3(0.47%) | 9.73E-04 |
| ko00643 | Styrene degradation | 2(0.31%) | 7.83E-04 |
KEGG pathway analysis of DEGs expressed only in group A, not in other groups
| Pathway ID | Pathway | DEGs with pathway annotation (295) | |
|---|---|---|---|
| ko05164 | Influenza A | 28(9.49%) | 5.35E-04 |
| ko04145 | Phagosome | 22(7.46%) | 6.31E-04 |
| ko05202 | Transcriptional misregulation in cancer | 22(7.46%) | 4.04E-04 |
| ko05133 | Pertussis | 16(5.42%) | 2.83E-03 |
| ko04668 | TNF signaling pathway | 15(5.08%) | 9.31E-05 |
| ko04380 | Osteoclast differentiation | 15(5.08%) | 2.81E-03 |
| ko05145 | Toxoplasmosis | 14(4.75%) | 2.22E-03 |
| ko04640 | Hematopoietic cell lineage | 14(4.75%) | 1.00E-04 |
| ko05222 | Small cell lung cancer | 13(4.41%) | 6.04E-04 |
| ko05322 | Systemic lupus erythematosus | 12(4.07%) | 1.21E-03 |
| ko05150 | 11(3.73%) | 5.12E-04 | |
| ko04657 | IL-17 signaling pathway | 11(3.73%) | 3.98E-04 |
| ko05130 | Pathogenic Escherichia coli infection | 8(2.71%) | 1.33E-03 |
| ko05321 | Inflammatory bowel disease (IBD) | 8(2.71%) | 2.66E-03 |
| ko05340 | Primary immunodeficiency | 7(2.37%) | 2.76E-05 |
| ko01523 | Antifolate resistance | 6(2.03%) | 4.41E-04 |
| ko00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 4(1.36%) | 1.23E-03 |
KEGG pathway analysis of DEGs expressed only in group SA, not in other groups
| Pathway ID | Pathway | DEGs with pathway annotation (293) | |
|---|---|---|---|
| ko00240 | Pyrimidine metabolism | 10(3.41%) | 8.46E-04 |
| ko05144 | Malaria | 9(3.07%) | 1.24E-05 |
| ko00760 | Nicotinate and nicotinamide metabolism | 7(2.39%) | 5.73E-04 |
| ko05340 | Primary immunodeficiency | 5(1.71%) | 1.27E-03 |
| ko00500 | Starch and sucrose metabolism | 5(1.71%) | 1.13E-03 |
| ko00521 | Streptomycin biosynthesis | 4(1.37%) | 5.95E-05 |
| ko00640 | Propanoate metabolism | 4(1.37%) | 1.29E-03 |
| ko01210 | 2-Oxocarboxylic acid metabolism | 4(1.37%) | 4.26E-04 |
| ko00524 | Neomycin, kanamycin and gentamicin biosynthesis | 3(1.02%) | 4.86E-05 |
| ko00770 | Pantothenate and CoA biosynthesis | 3(1.02%) | 1.90E-03 |
| ko00254 | Aflatoxin biosynthesis | 2(0.68%) | 1.14E-03 |
| ko00363 | Bisphenol degradation | 1(0.34%) | 0.00E+ 00 |
| ko02026 | Biofilm formation - Escherichia coli | 1(0.34%) | 1.03E-03 |
KEGG pathway analysis of DEGs expressed only in group S & A, not in other groups
| Pathway ID | Pathway | DEGs with pathway annotation (238) | |
|---|---|---|---|
| ko04970 | Salivary secretion | 21(8.82%) | 1.12E-05 |
| ko05416 | Viral myocarditis | 16(6.72%) | 9.85E-05 |
| ko04940 | Type I diabetes mellitus | 13(5.46%) | 1.95E-04 |
| ko05320 | Autoimmune thyroid disease | 13(5.46%) | 2.31E-04 |
| ko05330 | Allograft rejection | 13(5.46%) | 1.09E-04 |
| ko05332 | Graft-versus-host disease | 13(5.46%) | 8.29E-05 |
| ko04612 | Antigen processing and presentation | 11(4.62%) | 2.46E-03 |
| ko04640 | Hematopoietic cell lineage | 10(4.20%) | 1.79E-03 |
| ko05322 | Systemic lupus erythematosus | 10(4.20%) | 1.95E-03 |
| ko04672 | Intestinal immune network for IgA production | 8(3.36%) | 1.71E-03 |
| ko00590 | Arachidonic acid metabolism | 7(2.94%) | 3.84E-04 |
| ko03050 | Proteasome | 7(2.94%) | 3.75E-07 |
| ko05310 | Asthma | 5(2.10%) | 2.10E-03 |
| ko02026 | Biofilm formation - Escherichia coli | 1(0.42%) | 6.84E-04 |
| ko00643 | Styrene degradation | 1(0.42%) | 2.34E-03 |
KEGG pathway analysis of DEGs expressed only in group S & SA, not in other groups
| Pathway ID | Pathway | DEGs with pathway annotation (97) | |
|---|---|---|---|
| ko04971 | Gastric acid secretion | 11(11.34%) | 7.79E-06 |
| ko04972 | Pancreatic secretion | 8(8.25%) | 0.001196 |
| ko05214 | Glioma | 7(7.22%) | 0.001021 |
| ko04976 | Bile secretion | 6(6.19%) | 0.000925 |
| ko04745 | Phototransduction - fly | 6(6.19%) | 0.001526 |
| ko02010 | ABC transporters | 5(5.15%) | 0.000153 |
| ko00512 | Mucin type O-glycan biosynthesis | 4(4.12%) | 0.000611 |
| ko00910 | Nitrogen metabolism | 2(2.06%) | 0.000775 |
| ko00640 | Propanoate metabolism | 2(2.06%) | 0.002456 |
| ko02020 | Two-component system | 2(2.06%) | 0.000155 |
| ko00254 | Aflatoxin biosynthesis | 1(1.03%) | 0.0022 |
| ko00627 | Aminobenzoate degradation | 1(1.03%) | 0.00193 |
KEGG pathway analysis of DEGs expressed only in group A & SA, not in other groups
| Pathway ID | Pathway | DEGs with pathway annotation (300) | P-value |
|---|---|---|---|
| ko04514 | Cell adhesion molecules (CAMs) | 38(12.67%) | 7.04E-06 |
| ko04144 | Endocytosis | 38(12.67%) | 5.67E-05 |
| ko05168 | Herpes simplex infection | 38(12.67%) | 2.46E-10 |
| ko05169 | Epstein-Barr virus infection | 37(12.33%) | 8.96E-11 |
| ko05203 | Viral carcinogenesis | 37(12.33%) | 1.99E-09 |
| ko04145 | Phagosome | 34(11.33%) | 1.88E-09 |
| ko05166 | HTLV-I infection | 34(11.33%) | 2.38E-05 |
| ko05416 | Viral myocarditis | 34(11.33%) | 2.91E-14 |
| ko04612 | Antigen processing and presentation | 30(10.00%) | 3.52E-14 |
| ko05320 | Autoimmune thyroid disease | 29(9.67%) | 1.94E-13 |
| ko04940 | Type I diabetes mellitus | 28(9.33%) | 7.70E-13 |
| ko05330 | Allograft rejection | 28(9.33%) | 1.86E-13 |
| ko05332 | Graft-versus-host disease | 28(9.33%) | 9.75E-14 |
| ko04650 | Natural killer cell mediated cytotoxicity | 27(9.00%) | 1.50E-08 |
| ko04142 | Lysosome | 12(4.00%) | 2.26E-03 |
| ko04110 | Cell cycle | 12(4.00%) | 1.37E-03 |
| ko04978 | Mineral absorption | 8(2.67%) | 2.40E-04 |
| ko05130 | Pathogenic Escherichia coli infection | 8(2.67%) | 1.49E-03 |
| ko00531 | Glycosaminoglycan degradation | 6(2.00%) | 8.14E-06 |
| ko00600 | Sphingolipid metabolism | 6(2.00%) | 3.45E-03 |
| ko00260 | Glycine, serine and threonine metabolism | 5(1.67%) | 1.06E-03 |
| ko03030 | DNA replication | 5(1.67%) | 1.61E-04 |
| ko00680 | Methane metabolism | 4(1.33%) | 4.44E-03 |
| ko03420 | Nucleotide excision repair | 4(1.33%) | 4.20E-03 |
| ko03430 | Mismatch repair | 4(1.33%) | 3.88E-04 |
| ko00511 | Other glycan degradation | 3(1.00%) | 3.76E-03 |
| ko02026 | Biofilm formation - Escherichia coli | 1(0.33%) | 1.08E-03 |
KEGG pathway analysis of DEGs expressed only in group S & A & SA, not in other groups
| Pathway ID | Pathway | DEGs with pathway annotation (512) | P-value |
|---|---|---|---|
| ko04110 | Cell cycle | 30(5.86%) | 4.13E-10 |
| ko05410 | Hypertrophic cardiomyopathy (HCM) | 29(5.66%) | 1.61E-05 |
| ko05414 | Dilated cardiomyopathy | 28(5.47%) | 0.000175 |
| ko00240 | Pyrimidine metabolism | 27(5.27%) | 2.40E-11 |
| ko00230 | Purine metabolism | 26(5.08%) | 0.001102 |
| ko04111 | Cell cycle - yeast | 22(4.30%) | 8.63E-10 |
| ko04657 | IL-17 signaling pathway | 17(3.32%) | 9.87E-05 |
| ko03030 | DNA replication | 17(3.32%) | 1.04E-15 |
| ko00512 | Mucin type O-glycan biosynthesis | 16(3.12%) | 1.26E-07 |
| ko04113 | Meiosis - yeast | 14(2.73%) | 1.49E-05 |
| ko01524 | Platinum drug resistance | 13(2.54%) | 0.001395 |
| ko00480 | Glutathione metabolism | 13(2.54%) | 0.002834 |
| ko01200 | Carbon metabolism | 13(2.54%) | 0.004116 |
| ko00520 | Amino sugar and nucleotide sugar metabolism | 13(2.54%) | 7.96E-06 |
| ko01230 | Biosynthesis of amino acids | 12(2.34%) | 0.000464 |
| ko00260 | Glycine, serine and threonine metabolism | 11(2.15%) | 5.98E-07 |
| ko03460 | Fanconi anemia pathway | 9(1.76%) | 0.00086 |
| ko03430 | Mismatch repair | 8(1.56%) | 9.24E-07 |
| ko00680 | Methane metabolism | 8(1.56%) | 8.77E-05 |
| ko03440 | Homologous recombination | 8(1.56%) | 0.000308 |
| ko00052 | Galactose metabolism | 7(1.37%) | 0.002908 |
| ko03420 | Nucleotide excision repair | 7(1.37%) | 0.000446 |
| ko00100 | Steroid biosynthesis | 7(1.37%) | 1.35E-06 |
| ko03050 | Proteasome | 5(0.98%) | 0.003347 |
| ko00630 | Glyoxylate and dicarboxylate metabolism | 4(0.78%) | 0.004109 |
| ko00900 | Terpenoid backbone biosynthesis | 4(0.78%) | 0.001549 |
| ko00643 | Styrene degradation | 2(0.39%) | 0.000404 |
| ko00909 | Sesquiterpenoid and triterpenoid biosynthesis | 2(0.39%) | 1.24E-05 |
| ko00660 | C5-Branched dibasic acid metabolism | 1(0.20%) | 0.000536 |
Fig. 6Validation of RNA-seq data by qPCR. To validate the RNA-seq data, the relative mRNA levels of 17 randomly selected DEGs in the gills of hybrid tilapia were examined by qPCR. The mRNA levels by qPCR are presented as the fold change compared with the mock-treated control after normalization against β -actin. The relative expression levels from the RNA-seq analysis were calculated as log2FC values. The gene nkai1 was calculated in two different groups. (Note: nkain1–1 was in a group C vs. A, nkain1–2 was in group C vs. SA; trpv4–1 was in group S vs. SA, trpv4–2 was in group C vs. S)
Primers of different expression genes used for the qRT-PCR analysis
| Genes | Forward primer sequence(5′-3′) | Reverse primer sequence(5′-3′) |
|---|---|---|
| TTCCTGGGACCGTGGAGTGT | GTCAGCCGCCATAACGATAC | |
| TGTGGCAGCATAAGGCAGAC | GGTTCCTACAGCCTTGGTGC | |
| TAACGGAAGGAGCGATGAAG | ATACTCGGACCAGGACTACG | |
| AGACCATTGGCTTTGCTGTG | GTGGGAACCAGCAGGTAGTG | |
| CAGGAGGACATCCAGCAGAG | CCAGGTCAGACTTGTTGCCC | |
| GCAGTCTGGACGCAAAGGAG | TCATCGTAAAGCACCAGCAC | |
| LOC100695158 | TCTACAGGAGCAAAGGGAGG | CTTGGTTCTTGTCATCGGAG |
| LOC100711562 | GTGTCTTCACGCCTCTTCCT | CTCGTCCCGTTTGTAGGCAT |
| CATCTCCCTTCAAACGACAG | CACTGAAGGCTGTGGCGATT | |
| LOC1007004832 | GTGGTGCTAAACAAAGTCCG | ATGCCCACGACATCCTCTTC |
| GAATACAACACGGTGGCTCA | GCCATCCACATCAGCAAAGT | |
| LOC100700363 | TGGTGGACAGACAGAAGTGC | CTCCATCACACAACAGCGGC |
| TTCAACACATCCCTCCATCG | CCAAAGAGAGCCAAGAGGAT | |
| GCACTGGGCAAGACCTACTC | TACGAGGTGGTTCCCAAGAC | |
| CCAGTCACAATGAGAACCGC | GTATGTGGGTATGGAGGCTT | |
| LOC100696021 | TCTGCTAAACCTGCTCACCG | ATAGTTCAGCCCACAGACCC |